These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27143711)

  • 1. Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia.
    Mor N; Tang C; Blitzer A
    Otolaryngol Head Neck Surg; 2016 Sep; 155(3):458-61. PubMed ID: 27143711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
    Lerner MZ; Lerner BA; Patel AA; Blitzer A
    Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
    Kirke DN; Kaye R; Blitzer A
    Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients.
    Patel AB; Bansberg SF; Adler CH; Lott DG; Crujido L
    Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):859-63. PubMed ID: 26024910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Patients Receiving Short-Interval Botulinum Toxin Chemodenervation Treatment for Laryngeal Dystonia and Essential Tremor of the Vocal Tract.
    Lagos-Villaseca A; Bhatt NK; Abdolhosseini P; Quinonez L; Paoletti MF; Gochman G; Johns MM; Rosen CA; Kao TC; Meyer TK
    JAMA Otolaryngol Head Neck Surg; 2023 Jul; 149(7):615-620. PubMed ID: 37227721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 2015 Aug; 125(8):1751-7. PubMed ID: 26200329
    [No Abstract]   [Full Text] [Related]  

  • 11. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
    Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
    Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
    Boutsen F; Cannito MP; Taylor M; Bender B
    J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
    Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
    JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
    French G; Bosch JD; Randall DR
    J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
    Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
    Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
    Kang MS; Lee SJ; Choi HS; Lim JY
    Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
    Dharia I; Bielamowicz S
    Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.